Is 2.5 Mg Of levitra Enough

vardenafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study


vardenafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

Introduction: Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. vardenafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH-LUTS.

Aims: This multinational Phase 3 study assessed effects of vardenafil 2.5 or 5 mg once daily on ED and BPH-LUTS in men with both conditions during 12 weeks of double-blinded therapy.

Methods: Men were ≥ 45 years old, sexually active, and experiencing ED for ≥ 3 months and BPH-LUTS for >6 months. Randomization (baseline) followed a 4-week placebo lead-in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co-primary and key secondary measures at end point (last post-baseline observation).

Main outcome measures: The co-primary measures were the International Index of Erectile Function-erectile function (IIEF-EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment-emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed.

Conclusions: vardenafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated.

© 2011 International Society for Sexual Medicine.

Comment in

Jones JS. Jones JS. Nat Rev Urol. 2011 Oct 25;8(12):651-2. doi: 10.1038/nrurol.2011.162. Nat Rev Urol. 2011. PMID: 22025171 No abstract available.

Similar articles

Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Porst H, et al. J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19. J Sex Med. 2013. PMID: 23782459 Clinical Trial.

Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L. Giuliano F, et al. J Sex Med. 2013 Mar;10(3):857-65. doi: 10.1111/jsm.12039. Epub 2013 Jan 24. J Sex Med. 2013. PMID: 23346990 Clinical Trial.

Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L. Brock G, et al. BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13. BJU Int. 2013. PMID: 23937669 Clinical Trial.

Carson CC, Rosenberg M, Kissel J, Wong DG. Carson CC, et al. Int J Clin Pract. 2014 Jan;68(1):94-103. doi: 10.1111/ijcp.12305. Int J Clin Pract. 2014. PMID: 24341303 Review.

Wang Y, Bao Y, Liu J, Duan L, Cui Y. Wang Y, et al. Low Urin Tract Symptoms. 2018 Jan;10(1):84-92. doi: 10.1111/luts.12144. Epub 2016 Nov 5. Low Urin Tract Symptoms. 2018. PMID: 29341503 Review.

Cited by

Chen Q, Mao Y, Zhou H, Tang S. Chen Q, et al. Int J Clin Pract. 2022 Nov 3;2022:9298483. doi: 10.1155/2022/9298483. eCollection 2022. Int J Clin Pract. 2022. PMID: 36419863 Free PMC article.

Fan Z, Shi H, Zhang J, Wang H, Wang J. Fan Z, et al. Front Pharmacol. 2022 Mar 7;13:763184. doi: 10.3389/fphar.2022.763184. eCollection 2022. Front Pharmacol. 2022. PMID: 35330833 Free PMC article. Review.

Cui J, Cao D, Bai Y, Wang J, Yin S, Wei W, Xiao Y, Wang J, Wei Q. Cui J, et al. Front Med (Lausanne). 2021 Oct 12;8:744012. doi: 10.3389/fmed.2021.744012. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34712682 Free PMC article.

Gaspar A, Silva J, Silva G, Anchelerguez R, Prats J, Sagaz A, Rovere E, Alastra M, Pino J, Jauregui A, Farrugia M, Villaroel F, Guareschi J, Vega M, Biasiori E, Moyano E, La Rosa A, Hreljac I, Vižintin Z. Gaspar A, et al. Neurourol Urodyn. 2021 Jan;40(1):278-285. doi: 10.1002/nau.24551. Epub 2020 Nov 10. Neurourol Urodyn. 2021. PMID: 33170523 Free PMC article.

Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary KT, Kaplan S, Gravas S, Chapple C, Gacci M. Sebastianelli A, et al. Curr Urol Rep. 2020 Oct 27;21(12):56. doi: 10.1007/s11934-020-01009-7. Curr Urol Rep. 2020. PMID: 33108544 Free PMC article. Review.


Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L. Giuliano F, et al. J Sex Med. 2013 Mar;10(3):857-65. doi: 10.1111/jsm.12039. Epub 2013 Jan 24. J Sex Med. 2013. PMID: 23346990 Clinical Trial.


vardenafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

Introduction: Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. vardenafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH-LUTS.

Aims: This multinational Phase 3 study assessed effects of vardenafil 2.5 or 5 mg once daily on ED and BPH-LUTS in men with both conditions during 12 weeks of double-blinded therapy.

Methods: Men were ≥ 45 years old, sexually active, and experiencing ED for ≥ 3 months and BPH-LUTS for >6 months. Randomization (baseline) followed a 4-week placebo lead-in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co-primary and key secondary measures at end point (last post-baseline observation).

Main outcome measures: The co-primary measures were the International Index of Erectile Function-erectile function (IIEF-EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment-emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed.

Conclusions: vardenafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated.

© 2011 International Society for Sexual Medicine.


Wang Y, Bao Y, Liu J, Duan L, Cui Y. Wang Y, et al. Low Urin Tract Symptoms. 2018 Jan;10(1):84-92. doi: 10.1111/luts.12144. Epub 2016 Nov 5. Low Urin Tract Symptoms. 2018. PMID: 29341503 Review.


Similar articles


PMID 24341303 Review.




18.05.2022 02:34:58

2022-05-18 02:34:58


Pharmacy Popitka Nomer 5 Tekst generic levitra mexico Deutsche Versandapotheke ==**|**==Best Effective Way To Take Pharmacy levitra 5mg avis forum Gold Max Female Reviews


Buy Pharmacy Brisbane Australia buy levitra using mastercard Gambar Obat Kuat ==**|**==Pharmacy Patent Lawsuit double dosage of levitra A Jej Pouzitie